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challenges When expanding 
transcatheter Aortic valve 
implantation to Younger Patients
Ole De Backer* and Lars Søndergaard
The Heart Center, Rigshospitalet, Copenhagen, Denmark
The rapid expansion of transcatheter aortic valve implantation (TAVI) has been based 
upon robust clinical evidence derived from randomized controlled trials and large-scale 
international and national registries. Over the past decade, TAVI has evolved into a safe 
and effective procedure with predictable and reproducible outcomes. As a consequence, 
the TAVI technology is increasingly used to treat patients with a lower risk profile and 
the volume of TAVI now exceeds surgical aortic valve replacement (SAVR) in some 
countries. It may be anticipated that, in the near future, the majority of patients with severe 
symptomatic aortic valve stenosis will undergo TAVI as first line therapy, regardless of 
their age and risk profile. This article identifies some of the specific challenges that lie 
ahead when considering expansion of TAVI to younger patients.
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Transcatheter aortic valve implantation (TAVI) has become an established therapeutic option 
for patients with symptomatic, severe aortic valve  stenosis (AS) who are at increased risk for 
conventional cardiac surgery (1–4). In recent years, the TAVI technology is also increasingly used 
to treat patients with a lower risk profile – this practice is supported by results from the NOTION, 
PARTNER-II and SURTAVI trials indicating that TAVI is a viable option for patients with a low 
to intermediate surgical risk profile (5–7).
Although TAVI, in many countries, has become the default therapy to treat AS patients aged 
75 years or more, there is currently increasing discussion on how far to push the limits when 
considering treating younger patients. Although the above-mentioned lower-risk TAVI trials 
included patients with a lower surgical risk score, the mean age of enrolled patients was not 
different compared to the early TAVI trials conducted in extreme or high risk patients (Figure 1) 
(1–7). When considering further expansion of TAVI indications to encompass younger patients 
aged 75 years or less, there are still some challenges ahead.
Based on currently available data, it can be stated that TAVI is non-inferior to surgery in 
terms of mortality and stroke, and is likely to be superior if a transfemoral approach is possible. 
Surgical patients more frequently experience major bleedings, acute kidney injury, and new-onset 
atrial fibrillation, whereas TAVI is associated with a higher rate of major vascular complications, 
paravalvular regurgitation, and pacemaker implantations (3–7). When considering expansion 
of TAVI to younger patients < 75 years, it will be a must to obtain predictable and outstanding 
results, also for these latter procedural outcomes.
Over the past decade, the TAVI technology has matured; however, technological improvements 
have not come to a halt yet. New TAVI devices with lower-profile delivery systems have increased 
the proportion of patients who can be treated by transfemoral approach and have significantly 
reduced vascular complications (8). Newer generation TAVI devices also have an additional 
sealing skirt, which reduces the risk of paravalvular regurgitation, (9) and are often repositionable, 
which can result in higher implants thereby reducing the risk of conduction disorders (10). 
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Furthermore, procedural outcomes have improved because of 
increased operator experience and developments in cardiac and 
vascular imaging, particularly using multidetector CT.
As TAVI would move into younger AS populations, one 
pitfall may be that treating bicuspid valves would become an 
increasing part of practice – with an estimate of 30–50% in 
those patients aged 75 years or less (11). Importantly, patients 
with bicuspid AS have typically been excluded from the large 
randomized controlled trials. Today, only limited data exist on 
outcomes of TAVI in bicuspid AS. In a recent meta-analysis 
of 13 observational studies, short-term outcome data indicated 
that TAVI for bicuspid AS is associated with high device success 
rates and a good safety profile. Mortality at 30 days was low and 
comparable to that achieved with the newest generation TAVI 
devices in tricuspid AS. However, there was a trend towards 
higher rates of significant paravalvular regurgitation (12%) 
and permanent pacemaker requirement (18%) in bicuspid 
AS cohorts undergoing TAVI (12). An important issue when 
considering TAVI in bicuspid AS is the assessments of these 
patients’ anatomy and the modification of the TAVI technique, 
with specific attention to valve deployment and positioning. 
In order to overcome the limitations of the current generation 
TAVI devices with regards to paravalvular regurgitation and 
pacemaker requirement, the design of specific TAVI devices to 
treat bicuspid anatomy will become crucial.
Finally, extension of TAVI to younger patients with longer 
life-expectancy also raises the issue of durability. In 2016, some 
concern was raised about potential poor long-term durability of 
transcatheter heart valves – however, these results were based on 
less than 50 first generation valves and only echocardiographic 
findings were used to define valve degeneration (13) – which is 
in contrast with the “need for re-intervention” used as definition 
for surgical valve degeneration. Importantly, since then, robust 
5 year follow-up data have come available demonstrating 
continued valve durability with low rates of hemodynamic 
valve dysfunction and/or re-intervention, and this for both 
balloon-expandable and self-expanding transcatheter heart 
valves (1–3, 14).
Recently, ESC, EAPCI and EACTS have published a consensus 
on standard definitions of structural valve deterioration (SVD) 
and bioprosthetic valve failure (BVF) in order to assess long-term 
durability of transcatheter and surgical aortic bioprosthesis (15). 
There should be clear distinction between SVD (the principal 
etiology) and BVF (the clinical correlate). SVD includes 
permanent (irreversible) intrinsic changes of the valve (i.e., 
leaflet tear, calcification, pannus deposition, flail, or fibrotic 
leaflet) leading to degeneration and/or dysfunction, which in 
turn may result in stenosis or intra-prosthetic regurgitation. 
The term BVF integrates severe SVD (i.e., the etiology) with its 
clinical consequences – thereby avoiding over-interpretation of 
valve-related outcomes in asymptomatic patients with no clinical 
impact – and is recommended to be used as the main outcome 
of interest in studies assessing the long-term performance of 
TAVI and SAVR. Importantly, BVF may occur in the setting of 
SVD but also as the consequence of pathophysiological processes 
unrelated to SVD, such as thrombosis, endocarditis or non-
structural valve dysfunction. BVF includes any of the following: 
(1) bioprosthetic valve dysfunction at autopsy, very likely related 
to the cause of death, or “valve- related death”; (2) aortic valve 
re-intervention (i.e., valve-in-valve TAVI, paravalvular leak 
closure or SAVR); and (3) severe hemodynamic SVD.
These definitions have been applied to the NOTION trial 
(7) – including 80% low risk patients – showing that, after five 
years, the rate of SVD was lower in transcatheter heart valves 
as compared to surgical aortic bioprosthesis (3.9% vs. 26.1%, 
respectively; p < 0.001), whereas the rate of BVF was similar in 
both groups (8.9% vs. 9.5%, respectively; p = 0.89) – as presented 
at EuroPCR 2017.
As a large portion of the younger AS patients has a bicuspid 
valve, data on transcatheter heart valve durability and long-term 
outcomes in this specific cohort will also become essential. Given 
the anatomical characteristics of a stenotic bicuspid aortic valve, a 
concern may be that the implanted transcatheter heart valve may 
not fully expand or not become fully circular with asymmetric 
leaflets as a result. Although this should not necessarily lead to 
immediate valvular dysfunction, it has recently been reported 
that asymmetrical leaflet expansion may be associated with 
an increased risk of subclinical leaflet thrombosis (16). In 
FiGUre 1 |  Surgical risk and age profile in the different large randomized 
controlled TAVI trials, indicating the mean STS surgical risk score (in %) and 
mean age (in years) for the TAVI group in every respective study. STS, Society 
of Thoracic Surgeons; TAVI, transcatheter aortic valve implantation.
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addition, leaflet asymmetry may also have an impact on long-
term valve durability. This is still important missing information 
when one considers treating a younger bicuspid AS patient 
with TAVI.
In conclusion, the rapid expansion of TAVI has been based 
upon robust clinical evidence derived from randomized 
controlled trials and large-scale international and national 
registries. Over the past decade, TAVI has evolved into a safe 
and effective procedure with predictable and reproducible 
outcomes. As a consequence, the volume of TAVI now exceeds 
SAVR in some countries (17). It may be anticipated that, in the 
near future, the majority of patients with severe symptomatic 
AS will undergo TAVI as first line therapy, regardless of their 
age and risk profile. This article identifies some of the specific 
challenges that lie ahead when considering expansion of TAVI 
to younger patients (Figure  2). With ongoing developments 
of the TAVI technology, it can be expected that most of these 
obstacles will be overcome within the next decade. Still, it will 
be essential to provide the necessary clinical evidence – within 
the framework of a randomized trial – comparing TAVI with 
SAVR. Although large TAVI trials have been initiated by Edwards 
Lifesciences (USA) and Medtronic (USA) in low-risk AS cohorts, 
this is not a guarantee that young patients will be enrolled. In 
additon, patients with bicuspid AS are excluded from these trials. 
Currently, the only large randomized controlled trial comparing 
TAVI with SAVR in low-risk, younger patients ≤ 75 years of age, 
not excluding bicuspid valves, is the NOTION-2 trial (ClinTrials.
Gov: NCT02825134). This randomized trial should provide the 
needed clinical evidence to evaluate the use of TAVI in young, 
low-risk AS patients.
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FiGUre 2 |  Summary figure: challenges when expanding transcatheter aortic valve implantation to younger patients.
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